The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.
| Autor: | O'Neill CE; Lambe Institute for Translational Research, Discipline of Pathology, School of Medicine, University of Galway, Galway, Ireland., Sun K; Houston Methodist Research Institute, Houston, TX, United States.; Dr Mary and Ron Neal Cancer Center, Houston Methodist Hospital, Houston, TX, United States., Sundararaman S; Lambe Institute for Translational Research, Discipline of Pathology, School of Medicine, University of Galway, Galway, Ireland., Chang JC; Houston Methodist Research Institute, Houston, TX, United States.; Dr Mary and Ron Neal Cancer Center, Houston Methodist Hospital, Houston, TX, United States., Glynn SA; Lambe Institute for Translational Research, Discipline of Pathology, School of Medicine, University of Galway, Galway, Ireland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in physiology [Front Physiol] 2024 Mar 27; Vol. 15, pp. 1358850. Date of Electronic Publication: 2024 Mar 27 (Print Publication: 2024). |
| DOI: | 10.3389/fphys.2024.1358850 |
| Abstrakt: | The human epidermal growth factor receptor (HER) family consists of four members, activated by two families of ligands. They are known for mediating cell-cell interactions in organogenesis, and their deregulation has been associated with various cancers, including breast and esophageal cancers. In particular, aberrant epidermal growth factor receptor (EGFR) and HER2 signaling drive disease progression and result in poorer patient outcomes. Nitric oxide (NO) has been proposed as an alternative activator of the HER family and may play a role in this aberrant activation due to its ability to induce s-nitrosation and phosphorylation of the EGFR. This review discusses the potential impact of NO on HER family activation and downstream signaling, along with its role in the efficacy of therapeutics targeting the family. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 O’Neill, Sun, Sundararaman, Chang and Glynn.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|